PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

Somatic mutations affect key pathways in lung adenocarcinoma

Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551

Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer

Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors

Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442

Characterizing the cancer genome in lung adenocarcinoma

Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105

The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway

Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 933

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

Engelman, J. A., & Janne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2248 · Cited by 706

Signaling networks assembled by oncogenic EGFR and c-Met

Guo, A., Villén, J., Kornhauser, J. M., Lee, K. A., Stokes, M. P., Rikova, K., Possemato, A. P., Nardone, J., Innocenti, G., Wetzel, R. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707270105 · Cited by 511

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

She, Q., Solit, D. B., Ye, Q., O'Reilly, K. E., Lobo, J. M., & Rosen, N. X. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.006 · Cited by 416

Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient

Tao, J., Sun, D., & Hou, H. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13583 · Cited by 5

Development of triazole-based PKC-inhibitors to overcome resistance to EGFR inhibitors in EGFR-mutant lung cancers.

Lee, P., Kumar, V., Sivakumar, G., Tseng, T.-Y., Li, Y., Jiang, Y.-C., Hsiao, Y., Lin, H., Chang, C., & Hung, M. (2023) · PubMed Central · Cited by 5

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer

Kobayashi, K. (2023) · Journal of Respiration · doi:10.3390/jor3040021 · Cited by 6

Targeted therapy in nonsmall cell lung cancer

Puri, T. (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_258_17 · Cited by 5

Clinical Efficacy and Possible Applications of Genomics in Lung Cancer

Alharbi, K. K. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.5.1693 · Cited by 5

[Advance in microRNAs and EGFR-TKIs secondary resistance research in non-small cell lung cancer].

Duan, X., & Shi, J. (2014) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2014.12.07 · Cited by 5

Molekulardiagnostik des Lungenkarzinoms zur Therapiestratifizierung

Heukamp, L. C., & Büttner, R. (2009) · Der Pathologe · doi:10.1007/s00292-009-1241-1 · Cited by 5

PTEN decreases NR2F1 expression to inhibit ciliogenesis during EGFRL858R-induced lung cancer progression

Tran, T. N. P., & Hung, J. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06610-z · Cited by 5

Understanding lung cancer molecular subtypes

Pender, A., & Popat, S. (2014) · Clinical Practice · doi:10.2217/cpr.14.39 · Cited by 4

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations

Hung, M., Lung, J.-H., Lin, Y., Fang, Y., Hsieh, M., & Tsai, Y. (2016) · Medicine · doi:10.1097/md.0000000000003991 · Cited by 4

Targeted Therapy for Non-Small Cell Lung Cancer

Kim, J. S., & Kang, E. J. (2020) · Korean Journal of Medicine · doi:10.3904/kjm.2020.95.2.78 · Cited by 4

Integrative Data Analytic Framework to Enhance Cancer Precision Medicine

Gaudelet, T., Malod‐Dognin, N., & Pržulj, N. (2021) · Network and Systems Medicine · doi:10.1089/nsm.2020.0015 · Cited by 4

[Research progress on resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].

Li, Y., & Song, L. (2012) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2012.02.08 · Cited by 3

Drug delivery and drug resistance: EGFR-tyrosine kinase inhibitors in non-small cell lung cancer

Olcay, E., Giovannetti, E., & Peters, G. J. (2010) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) · Cited by 3

Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography

Slade, R. L., Pisaneschi, F., Nguyen, Q., Smith, G. S. T., Carroll, L. S., Beckley, A., Kaliszczak, M. A., & Aboagye, E. O. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161427 · Cited by 3

Circulating tumor DNA analysis in patients with EGFR mutant lung cancer

Nanjo, S., & Bivona, T. G. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.106 · Cited by 3

Molekulardiagnostik zur Therapiestratifizierung des Lungenkarzinoms

Heukamp, L. C., Wolf, J., & Büttner, R. (2011) · Der Internist · doi:10.1007/s00108-010-2698-y · Cited by 3

Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects

Ulivi, P., Calistri, D., Zoli, W., & Amadori, D. (2010) · Journal of Nucleic Acids Investigation · doi:10.4081/jnai.2010.e10 · Cited by 4

Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

Iommelli, F., Rosa, V. D., Fonti, R., & Vecchio, S. D. (2014) · Clinical and Translational Imaging · doi:10.1007/s40336-014-0050-6 · Cited by 4

EGFR inhibition generates drug-tolerant persister cells by blocking AKT activity

(2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.1045 · Cited by 3

Synthetic lethality targeting LKB1 mutant and EGFR wild type human non-small cell lung cancer cells by glucose starvation and SGLT2 inhibitionPreprint

Ren, Y., Chen, J., Mo, X., Yang, Q., Chen, P., Lu, G. X., Tan, H. W. S., Yi, J., Yu, Q., Kim, Y., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/622126 · Cited by 3

Loss of SUV420H2 promotes EGFR inhibitor resistance in NSCLC through upregulation of MET via LINC01510Preprint

Pal, A. S., Agredo, A., Lanman, N. A., Clingerman, J., Gates, K., & Kasinski, A. L. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.17.995951 · Cited by 3

Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticityPreprint

Zhang, L., Chinnam, M., Balk, B., Zhang, X., Wang, Y., Shaurova, T., Alam, S., Pokharel, S., Singh, P., Jacobi, J. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.04.668485 · Cited by 3

Purified Cucurbitacin D Leads to Alterations of Apoptotic and Autophagic Genes Expression in MDA‐MB‐468 and MCF‐7 Human Breast Cancer Cells

Zeinali, E., Zargar, S. J., & Mozdoori, N. (2025) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.70009 · Cited by 2

Adenocarcinoma

Kerr, K. M. (2012) · Molecular pathology library · doi:10.1007/978-1-4614-3197-8_13 · Cited by 2

Molecular Biology and Genetics of Lung Cancer

Milanović, D. (2011) · Medical radiology · doi:10.1007/174_2011_310 · Cited by 2

Thyrosinkinaseinhibitoren in der Onkologie

Zander, T., & Hallek, M. J. (2011) · Der Internist · doi:10.1007/s00108-011-2818-3 · Cited by 2

[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].

Han, R., Wang, X., Zhong, D., Zhao, J., Chen, Z., Sun, L., Wang, J., & Zhang, J. (2012) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2012.12.02 · Cited by 2

Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer

Fennell, D. A., & Swanton, C. (2012) · The EPMA Journal · doi:10.1186/1878-5085-3-6 · Cited by 2

[Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells].

Li, H., Wang, Q., Bao, H., Zhang, H., & Zhuang, Y. (2016) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2016.01.03 · Cited by 2

The Diagnostic and Therapeutic Potential of the Epigenetic Modifications of Lung Cancer–Related Genes

Li, S., & Zou, H. (2019) · Current Pharmacology Reports · doi:10.1007/s40495-019-00201-9 · Cited by 2

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC

Liao, B.-C., Hsu, W., Lee, J., Yang, C., Tsai, T.-H., Liao, W., Ho, C., Lin, C., Shih, J., Yu, C., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100099 · Cited by 2

An evaluation of patritumab deruxtecan for the treatment of EGFR -mutated non-small cell lung cancer

Waissengrin, B., & Reckamp, K. L. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2507833 · Cited by 1

LncPTEN1, a long non-coding RNA generated from PTEN, suppresses lung cancer metastasis through the regulation of EMT progress

Shen, Z., Zhong, A., Zhang, C., Tang, X., Zhao, X.-Y., Hou, Z.-Y., Liang, H., & Yin, Y.-X. (2025) · Non-coding RNA Research · doi:10.1016/j.ncrna.2025.05.011 · Cited by 1

Characterisation of mAb104 Antibody–Drug Conjugates Targeting a Tumour-Selective HER2 Epitope

Parakh, S., Huynh, N. T., Osellame, L. D., Cao, D., Rigopoulos, A., Gloria, B., Guo, N. Y., Scott, F. E., Liu, Z., Gan, H. K., et al. (2025) · Cancers · doi:10.3390/cancers17182995 · Cited by 1

Pioglitazone-Based Combination Approaches for Non-Small-Cell Lung Cancer

Aluru, S., Thyagarajan‐Sahu, A., & Sahu, R. P. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111416 · Cited by 1

Mutational profiling of EGFR and KRAS oncogenes in non-small cell lung cancer (NSCLC) cells obtained through fine needle aspiration cytology (FNAC)

Cemmi, F., Stella, G. M., Zorzetto, M., Inghilleri, S., Morbini, P., Dore, R., & Pozzi, E. (2010) · Università degli Studi di Pavia · doi:10.6092/2039-1404.123.666 · Cited by 1

Genomic Applications in Pulmonary Malignancies

Büttner, R., Odenthal, M., & Merkelbach‐Bruse, S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0727-4_24 · Cited by 1

Cytotoxicity and Radiosensitization of High Grade Glioma Cells by CI-1033, an Irreversible Pan-Erbb Inhibitor

van Vuurden, D. G. (2013) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000213 · Cited by 1

Overcoming Resistance to EGF Receptor Tyrosine Kinase Inhibitors in EGFR -mutated NSCLC

Saad, S., Huang, K., & Halmos, B. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.35 · Cited by 1

Morphological characterization and molecular profiling of malignant pericardial effusion in patients with pulmonary adenocarcinoma

Xiong, J., Zhou, B. R., Li, L., Shi, D., Jiang, T., & Xue, G. (2019) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_69_19 · Cited by 1

Advances in the management of acquired resistance to EGFR-TKI in non-small cell lung cancer

Zhou, F., & Zhou, C. (2015) · Oncology and Translational Medicine · doi:10.1007/s10330-015-0052-5 · Cited by 1

Prevalence and Factors Associated with the Loss of PTEN Expression in Patients with Lung Cancer

Kiatpanabhikul, T., & Bunyayothin, W. (2021) · Siriraj Medical Journal/San Sirirat · doi:10.33192/smj.2022.7 · Cited by 1

EGFR Resistance

Bourdeanu, L., Liu, E. Y., Brint, S., & Langdon, D. E. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-70142-4_4 · Cited by 1

Prise en charges des patients présentant une résistance aux TKI de l’EGFR

Barlési, F. (2011) · Revue de Pneumologie Clinique · doi:10.1016/s0761-8417(11)70008-6 · Cited by 1

[Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].

Ni, L., & Nie, L. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.02.02 · Cited by 2

Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non‐Small Cell Lung Cancer

Massarelli, E. (2014) · Lung Cancer · doi:10.1002/9781118468791.ch27 · Cited by 1

Signal Transduction in Disease

Ganey, P. E., & Misek, S. A. (2019) · Wiley eBooks · doi:10.1002/9781119060208.ch4 · Cited by 1

Targeting 14-3-3ζ overcomes resistance to EGFR-TKI in lung adenocarcinoma via BMP2/Smad/ID-1 signalingPreprint

Cui, J., Song, Y., Han, X., Hu, J., Chen, Y., Chen, X., Xu, X., Xing, Y., Lu, H., & Cai, L. (2020) · doi:10.21203/rs.2.23664/v1 · Cited by 1

Acquired Intergenic ANK3-RET Fusion as a Pralsetinib-Responsive Mechanism of Resistance to Osimertinib in EGFR-Mutated NSCLCPreprint

Urbanska, E. M., Sørensen, J. B., Melchior, L. C., Costa, J. C., & Santoni‐Rugiu, E. (2021) · Preprints.org · doi:10.20944/preprints202111.0052.v1

Correction: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

(2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0822 · Cited by 1

Transferrin receptor-based circulating tumor cell enrichment provides a snapshot of the molecular landscape of solid tumors and correlates with clinical outcomesPreprint

Galletti, G., Halima, A., Gjyrezi, A., Zhang, J., Zimmerman, B., Worroll, D., Kallergi, G., Bareja, R., Ocean, A. J., Saxena, A., et al. (2024) · medRxiv · doi:10.1101/2024.06.16.24309003 · Cited by 1

PDGFRb regulation as a mode of resistance to EGFR inhibition in Glioblastoma

Akhavan, D. (2012) · eScholarship (California Digital Library)

Identifiying oncogenic drivers in NSCLC cells harboring EGFR kinase domain mutation with resistance to EGFR TKI and mesenchymal phenotype

Gao, Y. (2014)

Análise da expressão, amplificação e deleção de EGFR e sua co-expressão com IL13R2 em astrocitomas

Carvalho, P. O. (2009) · doi:10.11606/t.5.2009.tde-25022010-165020

Strategy on Patients with EGFR Mutation

Früh, M., Zhou, Q. H., Leung, L. K. S., & Mok, T. S. K. (2014) · Springer eBooks · doi:10.1007/978-3-319-06062-0_9

Deregulated signaling networks in lung cancer

Singh, A. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9780511979811.028

Applying Biomarker Testing to Clinical Practice in Lung Cancer

Vincenten, J. P. L., Smit, E. F., Ylstra, B., & Thunnissen, E. (2012) · Lung Cancer Management · doi:10.2217/lmt.12.23

New Treatment Strategy for Patients with EGFR -Mutant Lung Cancer

Ninomiya, T., Takigawa, N., Toyooka, S., Hotta, K., Tanimoto, M., & Kiura, K. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.63

Pathophysiologie und Molekulardiagnostik beim nichtkleinzelligen Lungenkarzinom

Heukamp, L. C., Wolf, J. M., & Büttner, R. (2011) · Der Onkologe · doi:10.1007/s00761-011-2032-x

The Importance of Autophagy in Breast Cancer Development and Treatment

Hait, W. N., & Yang, J. (2007) · Defense Technical Information Center (DTIC) · doi:10.21236/ada475903

Synergistic interactions of targeted therapy within signal transduction pathways

Glaysher, S. L. (2012) · UPT. Syiah Kuala University Library (Syiah Kuala University)

Resistance to EGFR TKIs

Cappuzzo, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-20741-4_3

Contrôle de la signalisation oncogénique du mutant L858R de l'EGFR par la protéine

Ozenne, P. (2011)

Phosphatidylinositol 3-Kinase (PI3K) as a therapeutic target in NSCLC

Stamatkin, C. W. (2014) · UKnowledge (University of Kentucky)

Current state of the evolving MMMN cancer progression models of cancer

Thiagalingam, S. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9780511979811.022

TYPES OF DNA DAMAGE

(2013) · CRC Press eBooks · doi:10.1201/b14587-17

Mechanism of Resistance to Targeted Molecular Therapy

Seike, M. (2017) · Springer eBooks · doi:10.1007/978-981-10-2002-5_13

Mechanisms of IKBKE Activation in Cancer

Challa, S. (2017) · Digital Commons - University of South Florida (University of South Florida)

Final amendment: Ambiguous specification of EGFR mutations compounded by nil or negligible fragmented gene counts and erroneous application of the Kappa statistic reiterates doubts on the veracity of the TEP-studyPreprint

Chakraborty, S. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/150904

Understanding the Biology Behind the EGFR to Improve NSCLC Patients’ Treatment

Verlicchi, A., & Addeo, A. (2017) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.1000286

Systems Biology in Translational Oncology: Computational and Experimental Study of EGFR and IGF1R Pathways in NSCLC Cell Lines

Bianconi, F., Perruccio, K., Ludovini, V., Baldelli, E., Bellezza, G., Flacco, A., Valigi, P., & Crinò, L. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)34213-7

Investigations into how best to target FGFR2 mutant endometrial cancer

Geng, X. (2017) · Queensland University of Technology · doi:10.5204/thesis.eprints.123437

In vitro model for resistance in oncogene-dependent tumors at the limit of radiological detectabilityPreprint

Müller, N., Brägelmann, J., Lorenz, C., Michel, U. P., Plenker, D., Ortiz‐Cuaran, S., Weiss, J. M., Büttner, R., Peifer, M., Thomas, R. K., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/756593

Understanding the response to EGFR targeting therapy in non-small-cell lung cancer using -omics approach

Tran, Y. Z. (2020) · Figshare

Cross-platform Screening for Novel Fluvastatin and Kinase Inhibitor Co-therapies in Cancer Cell Lines

Pong, J. T. (2014) · TSpace (University of Toronto)

Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients

Park, J. E., Hong, M. J., Lee, S. Y., Lee, J. H., Choi, J. E., Kang, H., Do, S. K., Jeong, J. Y., Shin, K. M., Lee, W. K., et al. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s329055

Lung Cancer

Dobra, K., & Hjerpe, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-76478-8_8

Lung Cancer

Dobra, K., & Hjerpe, A. (2011) · Springer eBooks · doi:10.1007/978-0-85729-697-9_8

Molekulardiagnostik des Lungenkarzinoms zur Therapiestratifizierung

Heukamp, L. C., & Büttner, R. (2010) · Onkopipeline · doi:10.1007/s15035-010-0185-5

Research Progress of Acquired EGFR-TKI Resistance in Patients with Advanced Lung Adenocarcinoma

王, 康. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.119578

Apoptosis signaling in EGFR inhibitor resistance in NSCLC

Aka, Y., Karakaş, B., & Kütük, Ö. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822833-3.00001-2

Supplementary Methods, Figure Legends 1-3 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation

Sos, M. L., Rode, H. B., Heynck, S., Peifer, M., Fischer, F., Klüter, S., Pawar, V. G., Reuter, C., Heuckmann, J. M., Weiss, J. M., et al. (2023) · doi:10.1158/0008-5472.22385264

PTEN decreases NR2F1 expression to inhibit ciliogenesis during EGFRL858R-induced lung cancer progressionPreprint

Hung, J., & Tran, T. T. T. (2023) · Research Square · doi:10.21203/rs.3.rs-3244458/v1

Comprehensive transcriptomic profiling of liver cancer identifies that histone and PTEN are major regulators of SCU‑induced antitumor activity

Ha, S. E., Paramanantham, A., Kim, H. H., Bhosale, P. B., Park, M. Y., Abusaliya, A., Heo, J., Lee, W. S., & Kim, G. S. (2024) · Oncology Letters · doi:10.3892/ol.2024.14227

Editor’s Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, J. M., Fischer, F., Frommolt, P., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-5044

AKT1 Functional Polymorphism (rs2494750) Influences Clinical Outcomes in Patients With Advanced Lung Cancer Treated With EGFR Inhibitors

Choi, S. H., Choi, J. E., Hong, M. J., Lee, J. H., Kang, H., Do, S. K., Lee, W. K., Park, J. E., Lee, Y. H., Seo, H., et al. (2025) · Journal of Korean Medical Science · doi:10.3346/jkms.2025.40.e184 · Cited by 1

Effectiveness of afatinib after long-term gefitinib treatment for EGFR L858R and S768I compound mutation-positive lung adenocarcinoma: A case report

Dai-Shinozaki, A., Sakakibara‐Konishi, J., Hatanaka, K. C., Wakabayashi, K., Shinagawa, N., Matsuno, Y., Hatanaka, Y., & Konno, S. (2025) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2025.102249

Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapy

Pan, K., Xu, B., Lou, Y. L. G., Xue, J., Jin, X., Dang, M., Pan, S.-Y., Huang, Z., & Chen, X. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117562

Etude de l'impact de la perte d'expression de PTEN sur la réponse au cetuximab et l'induction de l'angiogenèse par un modèle cellulaire de carcinome épidermoïde de la tête et du cou

Mriouah, J. (2010) · theses.fr (ABES) · doi:10.70675/60888855z0387z4f1fz9a9bz4eacc3cd6fa9

Mécanismes de résistance au cetuximab et influence des associations de traitement dans des lignées cellulaires de cancers de voies aérodigestives supérieures

Rebucci, M. (2010) · doi:10.70675/40cbec34zee14z4240za39az8ba5064c7e61

Rôle des calpaïnes extracellulaires dans la progression des adénocarcinomes lépidiques

Ruppert, A.-M. (2015) · theses.fr (ABES) · doi:10.70675/6082601cze5b6z41e9zb588zf90c85ff07c9

Compréhension des étapes précoces de la résistance adaptative aux inhibiteurs de tyrosine kinase de l'EGFR dans les cancers bronchiques

Figarol, S. (2020) · theses.fr (ABES) · doi:10.70675/9b097a88z7be2z4f00z913fze60d534fa601

Molecular mechanisms of drug-tolerance to EGFR-targeted therapies in lung adenocarcinoma

Léonce, C. (2021) · theses.fr (ABES) · doi:10.70675/0611e924z7044z428cz90dcz9235e0a4b5a2

Caractérisation des facteurs de variation de l’efficacité et de la toxicité des thérapies anticancéreuses dans le cancer bronchique non à petites cellules

Barthélémy, D. (2023) · theses.fr (ABES) · doi:10.70675/16950651z7d96z48ebz9ff2z79fc7f898c51

Loss of PTEN as an Independent Poor Prognosis Indicator in Lung Adenocarcinoma, but Not in Squamous Cell Carcinoma, Is Associated with an Immunosuppressive Tumor Microenvironment and Distinct Co-Mutational Profiles

Houry, M., Silva, S. J., Artola, M., Behrens, C., Politi, K. A., Wistuba, I. I., Montuenga, L., Expósito, F., & Calvo, A. (2026) · Medical Sciences · doi:10.3390/medsci14020254

Phosphatases of regenerating liver downregulate PTEN to promote tumorigenesis

Abou‐Shanab, A. M., Yu, J., Bai, Y., & Zhang, Z. (2026) · Biochemical Society Transactions · doi:10.1042/bst20250538

Risk Stratification and Strategies Towards Front-Line Therapy of EGFR-Mutant NSCLC: A Narrative Review

Taing, K., Lam, H. Y., & Hsu, R. C. (2026) · Cancers · doi:10.3390/cancers18142285

Mycoplasma infection drives EGFR-TKI resistance through convergent transcriptomic reprogramming in non-small cell lung cancer

Wang, B., Donati, V., Gregori, A., Leonetti, A., Pastore, A., Deng, D., & Giovannetti, E. (2026) · iScience · doi:10.1016/j.isci.2026.116999

Co-mutation landscape and prognostic impact of genomic complexity in EGFR-mutant non-small cell lung cancer

Liu, K., Huang, G., Xie, B., Wang, D., Li, Z., Chen, S., Wang, J., Li, Z., Huang, T., & Huang, L. (2026) · BMC Cancer · doi:10.1186/s12885-026-16715-7

Editor’s Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, J. M., Fischer, F., Frommolt, P., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-5044

Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation

Izumi, H., Kanda, R., Murakami, Y., Morimoto, Y., & Ono, M. (2014) · European Respiratory Journal · doi:10.1183/13993003/erj.44.suppl_58.p508 · Cited by 1

Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations

Yamamoto, C., Basaki, Y., Kawahara, A., Nakashima, K., Kage, M., Izumi, H., Kohno, K., Uramoto, H., Yasumoto, K., Kuwano, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0043 · Cited by 155

[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].

Han, R., Wang, X., Zhong, D., Zhao, J., Chen, Z., Sun, L., Wang, J., & Zhang, J. (2012) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2012.12.02 · Cited by 2

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells

Tabara, K., Kanda, R., Sonoda, K., Kubo, T., Murakami, Y., Kawahara, A., Azuma, K., Abe, H., Kage, M., Yoshinaga, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041017 · Cited by 70